Protocol Ledger

NCT06962098 · Phase II · RECRUITING

Efficacy and Safety Study of Isuzinaxib in Subjects With DKD

Interventional Phase II clinical trial protocol NCT06962098 sponsored by Aptabio Therapeutics in Endocrinology, Obesity, and Metabolic, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2025-05-26 Enrollment: 186 participants (ESTIMATED) Federal Source: clinicaltrials.gov/study/NCT06962098
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)186 participants (ESTIMATED)
Disclosed U.S. Hospital Campuses vs Median (6 sites)1 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT06962098
Protocol FieldVerified Registry Value
NCT IdentifierNCT06962098
Consolidated Lead SponsorAptabio Therapeutics
Therapeutic Condition CohortEndocrinology, Obesity, and Metabolic
Clinical Trial PhasePhase II
Overall Recruitment StatusRECRUITING
Registered Enrollment186 participants (ESTIMATED)
Registered Start Date2025-05-26
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Canonical Hospital Campuses Listed on NCT06962098
Hospital Research SiteLocationSite Profile
Pusan National University HospitalBusan, South KoreaOpen Hospital Dossier ->

Search related sites and sponsors in the Interactive Directory, explore Endocrinology, Obesity, and Metabolic Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI